RIPK1 and RIPK3 are recognized as potential therapeutic targets for many diseases, given their broad linkage to the pathogenesis of inflammatory diseases, aging-related diseases, and even the normal aging process. This evidence concerns the gene RIPK1 and glycogen storage disease VI.